SG-2501 is under clinical development by Hangzhou Sumgen Biotech and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to GlobalData, Phase I drugs for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SG-2501’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SG-2501 overview

SG-2501 is under development for the treatment of hematological tumors like multiple myeloma, chronic lymphocytic leukemia, primary systemic amyloidosis, Waldenstrom macroglobulinemia, b-cell Hodgkin lymphoma, non-Hodgkin lymphoma, relapsed multiple myeloma, refractory multiple myeloma and diffuse large b-cell lymphoma. The drug candidate is a bi-specific monoclonal antibody and acts by targeting cell surface antigen CD38/CD47. The drug candidate is administered through intravenous route.

Hangzhou Sumgen Biotech overview

Hangzhou Sumgen Biotech formerly Hangzhou Shangjian Biotechnology Co Ltd is a drug developer, specializing in the development of therapeutic antibody drugs and the application of antibodies in immunotherapy and immunodiagnostics. Shangjian Biotechnology is headquartered in Hangzhou, Zhejiang, China.

For a complete picture of SG-2501’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.